CorMedix is an under-the-radar microcap biotech that recently successfully completed their Phase III for Neutrolin.
This completed milestone should enable the company to solve their short-term capital needs and pursue FDA approval for Neutrolin.
If successful in commercialization of Neutrolin, CorMedix stock could appreciate rapidly.
If Neutrolin is approved, CorMedix may also represent an attractive acquisition candidate.
At current share prices, CorMedix represents an interesting investment candidate with a projected exit of 12-18 months.
CorMedix Is A Drug And Medical Device Company Focusing On The Anti-Infective Space
CorMedix's (NYSEMKT:CRMD) first commercial product, Neutrolin®, available in Europe, addresses catheter-related blood stream infections. It recently successfully concluded a phase